Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis
- PMID:18611154
- DOI：10.。1086/590005
Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis
Abstract
Background:Multidrug-resistant (MDR) tuberculosis (TB) is more difficult to treat than is drug-susceptible TB. To elucidate the optimal therapy for MDR TB, we assessed the treatment outcomes and prognostic factors for patients with MDR TB.
Methods:本研究包括1995年1月至2004年12月，韩国首尔三星医院的三星医疗中心为三星医疗中心提供了个性化治疗方案的患者。要确定与有利的治疗结果，单变量比较和多个物流有关的预后因素进行回归。
结果：Of 155 patients, 18 (12%) had newly diagnosed MDR TB, 81 (52%) had previously received treatment with first-line drugs, and 56 (36%) had received treatment with second-line drugs. The isolated strains were resistant to a median of 5 drugs. Twenty-seven patients (17%) had extensively drug-resistant (XDR) TB at the start of treatment. Outcome assessment revealed that 102 patients (66%) were cured or completed therapy. The treatment success rates did not differ significantly between patients with non-XDR MDR TB and those with XDR TB (66% vs. 67%). Surgical resection was performed more frequently for patients with XDR TB than for those with non-XDR MDR TB (48% vs. 17%). Combined surgical resection, body mass index >/=18.5 (calculated as the weight in kilograms divided by the square of the height in meters), use of >4 effective drugs, and a negative sputum smear result were independent predictors of a favorable outcome.
Conclusions:Early aggressive treatment comprising at least 4 effective drugs and surgical resection, when indicated, may improve the outcome for patients with MDR TB or XDR TB.
类似的文章
-
广泛耐药对多药抗性结核病患者治疗结果的影响。临床感染者。2007年11月15日; 45（10）：1290-5。DOI：10.1086 / 522537。EPUB 2007年10月15日。 临床感染者。20.07. PMID:17968823
-
Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.int j感染dis。2009年3月13日（2）：170-5。DOI：10.1016 / J.IJID.2008.06.001。EPUB 2008 SEP 2。 int j感染dis。20.09. PMID:18768342
-
Surgical treatment for multidrug-resistant and extensive drug-resistant tuberculosis.Ann Thorac Surg。2010年5月; 89（5）：1597-602。DOI：10.1016 / J.Athoracsur.2010.02.020。 Ann Thorac Surg。2010年。 PMID:20.417785
-
广泛的耐药结核：新菌株，新挑战。Expert Rev Anti Infect Ther. 2008 Oct;6(5):713-24. doi: 10.1586/14787210.6.5.713. Expert Rev Anti Infect Ther. 2008. PMID:18847407 Review.
-
耐药结核病：过去，现在，未来。呼吸道学。2010年4月15日（3）：413-32。DOI：10.1111 / J.1440-1843.2010.01738.x。EPUB 2010 Mar 19。 呼吸道学。2010年。 PMID:20337989. Review.
Cited by52.文章
-
乌干达耐药结核病患者的营养性和治疗成功。感染药物抗蚀剂。2021 9; 14：3673-3681。DOI：10.2147 / IDR.S332148。ecollection 2021。 感染药物抗蚀剂。2021。 PMID:34526787. 免费PMC文章。
-
巴基斯坦广泛耐药结核的治疗结果：全国回顾性记录审查。前药房。2021 3月31日; 12：640555。DOI：10.3389 / FPHAR.2021.640555。ecollection 2021。 前药房。2021。 PMID:33867989 免费PMC文章。
-
Clinical Characteristics and Treatment Outcomes of Pathologically Confirmedaspergillus.Nodules.J Clin Med。20.20.Jul 10;9(7):2185. doi: 10.3390/jcm9072185. J Clin Med。2020。 PMID:32664449. 免费PMC文章。
-
Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes.开放论坛感染者。20.19 Apr 1;6(4):ofz118. doi: 10.1093/ofid/ofz118. eCollection 2019 Apr. 开放论坛感染者。2019年。 PMID:30949546 免费PMC文章。
-
坦桑尼亚多药抗性结核患者治疗成果的预测因素。Tuberc res治疗。2019年2月12日; 2019：3569018。DOI：10.1155 / 2019/3569018。Ecollection 2019。 Tuberc res治疗。2019年。 PMID:30891315 免费PMC文章。
Publication types
-
Actions
网格术语
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
-
Actions
物质
-
Actions
